Skinbiotherapeutics Share Discussion Threads

[someuwin] 16/8/2018 08:42

The study lasts 6 weeks. Therefore you have to assess the stability over a period at least that long (more like 2 months to be safe). So as its mid August now and they want to start the study in Sept, they're cutting it very fine.

[judijudi] 16/8/2018 08:42

24 hours is not a long time when in theory the cream product needs to survive for months/years in a bottle or tub

[alanrussell] 16/8/2018 08:39

someuwin, not the first time, this from that April RNS:

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"The incorporation of our SkInBiotix(R) technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year."

The company has successfully overcome many hurdles and I am confident they will resolve this. Just when is another matter.

[alanrussell] 16/8/2018 08:33

This is a very welcome announcement regarding the upscaling of manufacturing. I continue to hold with increased confidence however one matter seems rather concerning. Looking at the RNS below from April there does not seem to have been a great deal of progress on the stability front. Perhaps I am missing something, any thoughts?

RNS Number : 0875L
SkinBioTherapeutics PLC

17 April 2018
SkinBioTherapeutics plc

SkinBioTherapeutics' technology, SkinBiotix(R) , shows positive results in cream formulation

Manchester, UK - 17 April 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces that the 'cream' formulation of its SkinBiotix(R) technology has passed effectiveness studies in models of skin. The cream formulation will now undergo further testing for stability in the coming weeks. ........................

[someuwin] 16/8/2018 08:32

This is the first time I've heard them say that the human study is dependent on achieving certain stability parameters.

Is this RNS a precursor to a delay in the studies I wonder?

"The human study, which is due to commence in September, is subject to the Company's ongoing work to confirm stability of the current formulation over an extended timeframe. The Company expects to provide an update on this in the coming weeks."

[wrecktangle] 16/8/2018 08:28

hxxps://www.share-talk.com/share-news/share-talk-bulletin-board-heroes-13th-aug-2018/?utm_source=twitter&utm_medium=social&utm_campaign=SocialWarfare

35 - 40p boys.

[wrecktangle] 16/8/2018 08:15

Visainn on LSE who has a massive bonar for OPTI is trying to deramp SBTX and this RNS. You would think they (OPTI Investors) would be proud of their spin off (SBTX) making some positive movements. Haters will always hate but wait until this starts moving.

[woodaldo] 16/8/2018 07:54

I wouldn't be a bit surprised SOH is passing on his knowledge and lessons learned to Cathy at SBTX. Hence this RNS before the trials, I imagine because of this SBTX won't take as long as OPTI did to get to its position now.

[siennadelekat21] 16/8/2018 07:28

Very good point about the way they've sorted out the manufacturing scale up issues already shrewdmole... that certainly shows they're pretty damn confident in what the results of the trial will show. As stated, they really just need to prove that the cream/solution will last for extended periods - get that sorted and it certainly looks like a clear road to success.

[wrecktangle] 16/8/2018 07:25

Shrewdmole - The team has already have prepping and a mass production of the material. Their focus right now is mass produce and commercialization, which to me (and as you say) a huge vote of confidence about the human trials. No company in the world would focus on this part without passing trials....Lets hope it doesn't spike and instead moves steadily upwards to meet its daddy, OPTI, at around in triple digits soon. Terrific development.

[shrewdmole] 16/8/2018 07:08

Now I think one has to read between the lines.

Wouldn't you usually do human trials first ahead of scale up manufacturing tests which the manufacturing partner must be spending cash on?

They must be very confident of human trial success and at least if successful they will be ready to roll with a commercial agreement very quickly.

I wonder if the global at the table is involved in manufacture scale up tests.

Seems to me the final piece of the jigsaw is the trial and pretty much everything else is in place including the commercial deal....

S

[wrecktangle] 16/8/2018 07:08

This is exactly what I was waiting for. Excellent news from the OPTI spin off company. Who feels the share price has been moving like OPTI over the past few weeks? Wake me up when we get to a pound please.

"The Company, with its third party manufacturer, has now achieved significant manufacturing scale up, with no detrimental impact upon the active properties of the SkinBiotix® technology.
In addition the material, which to date has been manufactured and supplied in a liquid form, has now been successfully freeze dried. The ability to freeze dry the material is an important steps towards commercialisation as it enables mass production, storage and transportation."

[someuwin] 16/8/2018 07:03

SkinBioTherapeutics plc

Business update

Manchester, UK - 16 August 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to provide the following update:

Manufacturing

The Company, with its third party manufacturer, has now achieved significant manufacturing scale up, with no detrimental impact upon the active properties of the SkinBiotix® technology.
In addition the material, which to date has been manufactured and supplied in a liquid form, has now been successfully freeze dried. The ability to freeze dry the material is an important steps towards commercialisation as it enables mass production, storage and transportation.

The SkinBiotix® technology has been shown to be stable and effective within the cream formulation for 24 hours. The human study, which is due to commence in September, is subject to the Company's ongoing work to confirm stability of the current formulation over an extended timeframe. The Company expects to provide an update on this in the coming weeks.

Financial Position

The Company ended the 12 months to 30 June 2018 with a cash balance of £3.2m (31 December 2017: £3.6m).
The Company will publish its full year results in October.

Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:

"The progress we've made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study."

[shrewdmole] 16/8/2018 06:48

That chart looks quite attractive to me.

[manc10] 15/8/2018 21:17

when rayrac says buy you sell when rayrac says sell you buy simples . uk oil and gas lol well under placing price we need dave leningas to tweet

[rayrac] 15/8/2018 15:35

:)

jamjason14 Aug '18 - 16:13 - 2182 of 2188
0 3 0
why are you spamming both the sbtx and opti boards?

Because they are both from the same stable...where the horse is due to bolt!

Both claiming the impossible.

[slartybartfaster] 15/8/2018 11:06

Ray has a very good reason, TW bashes his Ukog. 100m over capitalised, or something along those lines. ie worthless POS which ray is up to his neck in. Of course these things always unfold and then ray will be penniless and blame everyone but himself.

[slartybartfaster] 15/8/2018 11:03

Im pretty sure the valuation was an 'industry valuation' that SOH referred to. I'm sure if elrico was here he would add when, where and by whom. May have been ray until judas poisoned his brain. :D

[rafboy] 15/8/2018 08:15

Yes, agreed he is just a basher for no good reason. Anyway, we are close to a decent rerate here I believe.

[shrewdmole] 15/8/2018 07:40

Ps just for info myself and a few others have tried to have a reasoned debate about Opti but he just can't have one its just blind bashing.

[shrewdmole] 15/8/2018 07:38

Jam

Took me a while but I finally filtered Ray yesterday.

Seems he has a vendetta against Tw so just blindly bashing Opti and Sbtx.

As has been said he's been saying don't touch Opti since it was 40p.

There's been some very very savvy buyers loading up well into the £1+ territory so who's right? Rayrac or experienced players.

S

[riskybusiness1] 14/8/2018 17:51

Strange isn't it. Trying to prevent people from making money even himself! Best to ignore as clearly has little knowledge on both co's and has no credibility or track record of success.Successful human clinicals will create a lot of value and seriously increase commercial interest. The likelihood of success imo is high due to the already successful lab tests which tested the product on dead people's skin (which stays alive outside the body for many weeks). The real risk is that it causes a reaction such as a rash but then again every individuals skin is different so could happen (as long as it is an insignificant number of subjects). There are rumours the cream is currently being used by the bod so looking good. A lot of value to come from here if you sit tight.

[jamjason] 14/8/2018 16:13

why are you spamming both the sbtx and opti boards?

[rayrac] 14/8/2018 15:47

You be careful new boy jam, I wouldn’t think you have a clue what you are getting into here. Either that or a minion!

[jamjason] 14/8/2018 13:58

Thank you shrewd, raf and risky for the replies, very helpful indeed.